Jessica Caciolla
Overview
Explore the profile of Jessica Caciolla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Exertier C, Salerno A, Antonelli L, Fiorillo A, Ocello R, Seghetti F, et al.
J Med Chem
. 2024 Jan;
67(1):402-419.
PMID: 38164929
Trypanothione reductase (TR) is a suitable target for drug discovery approaches against leishmaniasis, although the identification of potent inhibitors is still challenging. Herein, we harnessed a fragment-based drug discovery (FBDD)...
2.
Gobbi S, Martini S, Rozza R, Spinello A, Caciolla J, Rampa A, et al.
Molecules
. 2023 Apr;
28(7).
PMID: 37049810
Despite the significant outcomes attained by scientific research, breast cancer (BC) still represents the second leading cause of death in women. Estrogen receptor-positive (ER+) BC accounts for the majority of...
3.
Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy
Caciolla J, Martini S, Spinello A, Belluti F, Bisi A, Zaffaroni N, et al.
Eur J Med Chem
. 2022 Oct;
244:114802.
PMID: 36240547
The most frequently diagnosed breast cancer (BC) type in women expresses estrogen receptor (ER) and depends on estrogens for its growth, being classified as ER positive (ER+). The gold standard...
4.
Fiorillo A, Colotti G, Exertier C, Liuzzi A, Seghetti F, Salerno A, et al.
Front Mol Biosci
. 2022 Jul;
9:900882.
PMID: 35860359
Trypanothione reductase (TR) is a key factor in the redox homeostasis of trypanosomatid parasites, critical for survival in the hostile oxidative environment generated by the host to fight infection. TR...
5.
Salerno A, Seghetti F, Caciolla J, Uliassi E, Testi E, Guardigni M, et al.
J Med Chem
. 2022 Jul;
65(14):9507-9530.
PMID: 35816671
Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this...
6.
Caciolla J, Martini S, Spinello A, Pavlin M, Turrini E, Simonelli F, et al.
Eur J Med Chem
. 2021 Aug;
224:113733.
PMID: 34364162
Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) BC rely on suppressing...
7.
Caciolla J, Picone G, Farruggia G, Valenti D, Rampa A, Malucelli E, et al.
Bioorg Chem
. 2020 Nov;
106:104460.
PMID: 33229118
A small library of derivatives carrying a polycyclic scaffold recently identified by us as a new privileged structure in medicinal chemistry was designed and synthesized, aiming at obtaining potent MDR...
8.
Caciolla J, Bisi A, Belluti F, Rampa A, Gobbi S
Molecules
. 2020 Nov;
25(22).
PMID: 33207783
The current therapeutic approach for the treatment of hormone dependent breast cancer includes interference with estrogen receptors via either selective modulators or estrogens deprivation, by preventing their biosynthesis with aromatase...
9.
Caciolla J, Spinello A, Martini S, Bisi A, Zaffaroni N, Gobbi S, et al.
ACS Med Chem Lett
. 2020 May;
11(5):732-739.
PMID: 32435378
Breast cancer (BC) is the most diffused cancer type in women and the second leading cause of death among the female population. Effective strategies to fight estrogen responsive (ER+) BC,...
10.
Poli G, Lapillo M, Granchi C, Caciolla J, Mouawad N, Caligiuri I, et al.
J Enzyme Inhib Med Chem
. 2018 May;
33(1):956-961.
PMID: 29747534
Fyn tyrosine kinase inhibitors are considered potential therapeutic agents for a variety of human cancers. Furthermore, the involvement of Fyn kinase in signalling pathways that lead to severe pathologies, such...